At what serum phosphorus level should sevelamer be started in dialysis patients?

Phosphate Binder Initiation in Dialysis Patients

Start sevelamer (or any phosphate binder) when serum phosphorus exceeds 5.5 mg/dL in dialysis patients, after attempting dietary phosphorus restriction to 800-1,000 mg/day. 1

Target Phosphorus Range and Treatment Threshold

For dialysis patients (CKD Stage 5), the K/DOQI guidelines establish clear parameters:

• Target range: Maintain serum phosphorus between 3.5-5.5 mg/dL 1
• Treatment threshold: Initiate dietary restriction when phosphorus >5.5 mg/dL 1
• Phosphate binder indication: Start binders when phosphorus or PTH cannot be controlled despite dietary restriction 1

Stepwise Approach to Hyperphosphatemia

Step 1: Dietary Intervention First

When phosphorus exceeds 5.5 mg/dL, begin with dietary phosphorus restriction to 800-1,000 mg/day (adjusted for protein needs) 1. Monitor monthly during this intervention 1.

Step 2: Initiate Phosphate Binders

If phosphorus remains >5.5 mg/dL despite dietary compliance, prescribe phosphate binders 1. Both calcium-based binders and sevelamer are acceptable as primary therapy in dialysis patients 1.

Step 3: Sevelamer-Specific Dosing

According to FDA labeling, sevelamer starting doses are based on the degree of hyperphosphatemia 2:

• Phosphorus 5.5-7.5 mg/dL: Start 800 mg three times daily with meals
• Phosphorus 7.5-9.0 mg/dL: Start 1,600 mg three times daily with meals
• Phosphorus ≥9.0 mg/dL: Start 1,600 mg three times daily with meals

Titrate by one tablet per meal every 2 weeks based on response 2.

When to Prefer Sevelamer Over Calcium-Based Binders

Sevelamer should be the first-line choice (rather than calcium-based binders) in specific clinical scenarios 1:

1. Hypercalcemia: Corrected calcium >10.2 mg/dL 1
2. Low PTH: Intact PTH <150 pg/mL on 2 consecutive measurements 1
3. Vascular calcification: Severe vascular or soft-tissue calcifications present 1
4. Calcium overload: Already receiving >1,500 mg/day elemental calcium from binders 1

Important Clinical Considerations

Calcium Load Concerns

The 2018 KDIGO update emphasizes restricting calcium-based phosphate binders even in normophosphatemic patients, as studies showed potential harm from calcium loading 3. Total elemental calcium intake (diet plus binders) should not exceed 2,000 mg/day 1.

Combination Therapy

If phosphorus remains >5.5 mg/dL despite monotherapy with either calcium-based binders or sevelamer, use both in combination 1. This approach allows lower doses of each agent and reduces calcium load.

Severe Hyperphosphatemia

For phosphorus >7.0 mg/dL, consider aluminum-based binders as short-term rescue therapy (maximum 4 weeks, one course only), then transition to other binders 1. More frequent dialysis should also be considered 1.

Common Pitfalls to Avoid

1. Don't start binders without attempting dietary restriction first - this is the initial intervention unless phosphorus is severely elevated
2. Don't use calcium-based binders in hypercalcemic patients - this worsens calcium burden and vascular calcification risk
3. Don't exceed 1,500 mg/day elemental calcium from binders alone 1 - higher doses increase cardiovascular risk
4. Don't ignore the 2018 KDIGO caution 3 - avoid phosphate binders in normophosphatemic CKD patients not on dialysis, as studies showed potential harm

Monitor serum phosphorus monthly after initiating or adjusting therapy 1 to ensure adequate control while avoiding overtreatment.